We are analyzing https://link.springer.com/article/10.1007/s12032-013-0747-9.

Title:
S-1 plus CIK as second-line treatment for advanced pancreatic cancer | Medical Oncology
Description:
This study aimed to evaluate the efficacy and tolerability of S-1 (Tegafur, Gimeracil, and Oteracil Potassium Capsules) plus CIK (Cytokine-induced killer cells) in patients with advanced pancreatic cancer who had previously received gemcitabine-based therapy. In this prospective study, fifty-eight patients were randomly divided into two groups. One group (CT group) was given S-1 alone, and the other group (immuno-CT group) was given S-1 plus CIK. S-1 was administered orally twice a day at 80 mg/m2/day on days 1–21 of a 28-day cycle till disease progression or unacceptable toxicity occurred. CIK was given for one cycle of 28 days. The disease control rate for S-1 and CIK was 40.0 and 53.6 %, respectively (p = 0.621). The serum CA19-9 level decreased for more than 25 % was significantly different (33.3 and 60.7 % in CT group and immuno-CT group, respectively, p = 0.037). The median time to progression was 2.5 (95 % CI 2.3–2.8) and 2.9 (95 % CI 2.6–3.2) months (p = 0.037) for CT group and immuno-CT group, respectively. The median overall survival was 6.1 (95 % CI 5.7–6.5) and 6.6 (95 % CI 6.1–7.1) months (p = 0.09) for CT group and immuno-CT group, respectively. The difference in hematological toxicity, including leukocytopenia, anemia, and neutropenia, was insignificant between the two groups. In contrast, the differences in non-hematological toxicity, fatigue, and non-infective fever were significantly different between the two groups (p < 0.05). The S-1 plus CIK regimen was well tolerated in a second-line setting in patients with gemcitabine-refractory and advanced pancreatic cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Insurance
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, article, pubmed, google, scholar, pancreatic, patients, advanced, cas, group, study, oncol, secondline, treatment, cik, gemcitabinerefractory, clin, phase, gemcitabine, killer, privacy, cookies, content, wang, shi, therapy, access, metastatic, chemotherapy, jpn, information, publish, search, cells, immunoct, combination, immunotherapy, immunol, furuse, chemother, pharmacol, author, data, log, journal, research, october, meng, shengbin, jielin,

Topics {✒️}

xiao-yong tang & jing tian month download article/chapter dendritic cell-based vaccination cytokine-induced killer cells gemcitabine-refractory pancreatic cancer 2/neu-derived peptide epitopes advanced pancreatic carcinoma refractory pancreatic cancer killer cell activities metastatic pancreatic cancer advanced pancreatic cancer inoperable pancreatic cancer full article pdf related subjects privacy choices/manage cookies line therapy dendritic cells combining sheng-bin shi cancer chemother pharmacol cancer immunol immunother tumor selective cytotoxicity cancer chemotherapy advanced pancreas cancer clin cancer res outpatient-based regimen disease control rate pancreatic cancer neck cancer patients european economic area oteracil potassium capsules 80 mg/m2/day nat rev immunol conditions privacy policy article wang long term survival phase 1b study phase ii study jie-lin qi phase ii trial unacceptable toxicity occurred immunotherapy cisplatin versus gemcitabine kim hj accepting optional cookies oral 5-xuorouracil derivative supportive care versus line chemotherapy article log gemcitabine-refractory author information authors

Schema {🗺️}

WebPage:
      mainEntity:
         headline:S-1 plus CIK as second-line treatment for advanced pancreatic cancer
         description:This study aimed to evaluate the efficacy and tolerability of S-1 (Tegafur, Gimeracil, and Oteracil Potassium Capsules) plus CIK (Cytokine-induced killer cells) in patients with advanced pancreatic cancer who had previously received gemcitabine-based therapy. In this prospective study, fifty-eight patients were randomly divided into two groups. One group (CT group) was given S-1 alone, and the other group (immuno-CT group) was given S-1 plus CIK. S-1 was administered orally twice a day at 80 mg/m2/day on days 1–21 of a 28-day cycle till disease progression or unacceptable toxicity occurred. CIK was given for one cycle of 28 days. The disease control rate for S-1 and CIK was 40.0 and 53.6 %, respectively (p = 0.621). The serum CA19-9 level decreased for more than 25 % was significantly different (33.3 and 60.7 % in CT group and immuno-CT group, respectively, p = 0.037). The median time to progression was 2.5 (95 % CI 2.3–2.8) and 2.9 (95 % CI 2.6–3.2) months (p = 0.037) for CT group and immuno-CT group, respectively. The median overall survival was 6.1 (95 % CI 5.7–6.5) and 6.6 (95 % CI 6.1–7.1) months (p = 0.09) for CT group and immuno-CT group, respectively. The difference in hematological toxicity, including leukocytopenia, anemia, and neutropenia, was insignificant between the two groups. In contrast, the differences in non-hematological toxicity, fatigue, and non-infective fever were significantly different between the two groups (p < 0.05). The S-1 plus CIK regimen was well tolerated in a second-line setting in patients with gemcitabine-refractory and advanced pancreatic cancer.
         datePublished:2013-10-13T00:00:00Z
         dateModified:2013-10-13T00:00:00Z
         pageStart:1
         pageEnd:6
         sameAs:https://doi.org/10.1007/s12032-013-0747-9
         keywords:
            Pancreatic cancer
            Second-line treatment
            S-1
            CIK
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-013-0747-9/MediaObjects/12032_2013_747_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-013-0747-9/MediaObjects/12032_2013_747_Fig2_HTML.gif
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
               1357-0560
            volumeNumber:30
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Meng Wang
               affiliation:
                     name:Shan Dong Ji Ning First People’s Hospital
                     address:
                        name:Department of Internal Medicine, Shan Dong Ji Ning First People’s Hospital, Jining, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sheng-bin Shi
               affiliation:
                     name:Shan Dong Tumor Hospital
                     address:
                        name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jie-lin Qi
               affiliation:
                     name:Shan Dong Tumor Hospital
                     address:
                        name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Xiao-yong Tang
               affiliation:
                     name:Shan Dong Tumor Hospital
                     address:
                        name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jing Tian
               affiliation:
                     name:Shan Dong Tumor Hospital
                     address:
                        name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:S-1 plus CIK as second-line treatment for advanced pancreatic cancer
      description:This study aimed to evaluate the efficacy and tolerability of S-1 (Tegafur, Gimeracil, and Oteracil Potassium Capsules) plus CIK (Cytokine-induced killer cells) in patients with advanced pancreatic cancer who had previously received gemcitabine-based therapy. In this prospective study, fifty-eight patients were randomly divided into two groups. One group (CT group) was given S-1 alone, and the other group (immuno-CT group) was given S-1 plus CIK. S-1 was administered orally twice a day at 80 mg/m2/day on days 1–21 of a 28-day cycle till disease progression or unacceptable toxicity occurred. CIK was given for one cycle of 28 days. The disease control rate for S-1 and CIK was 40.0 and 53.6 %, respectively (p = 0.621). The serum CA19-9 level decreased for more than 25 % was significantly different (33.3 and 60.7 % in CT group and immuno-CT group, respectively, p = 0.037). The median time to progression was 2.5 (95 % CI 2.3–2.8) and 2.9 (95 % CI 2.6–3.2) months (p = 0.037) for CT group and immuno-CT group, respectively. The median overall survival was 6.1 (95 % CI 5.7–6.5) and 6.6 (95 % CI 6.1–7.1) months (p = 0.09) for CT group and immuno-CT group, respectively. The difference in hematological toxicity, including leukocytopenia, anemia, and neutropenia, was insignificant between the two groups. In contrast, the differences in non-hematological toxicity, fatigue, and non-infective fever were significantly different between the two groups (p < 0.05). The S-1 plus CIK regimen was well tolerated in a second-line setting in patients with gemcitabine-refractory and advanced pancreatic cancer.
      datePublished:2013-10-13T00:00:00Z
      dateModified:2013-10-13T00:00:00Z
      pageStart:1
      pageEnd:6
      sameAs:https://doi.org/10.1007/s12032-013-0747-9
      keywords:
         Pancreatic cancer
         Second-line treatment
         S-1
         CIK
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-013-0747-9/MediaObjects/12032_2013_747_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-013-0747-9/MediaObjects/12032_2013_747_Fig2_HTML.gif
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
            1357-0560
         volumeNumber:30
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Meng Wang
            affiliation:
                  name:Shan Dong Ji Ning First People’s Hospital
                  address:
                     name:Department of Internal Medicine, Shan Dong Ji Ning First People’s Hospital, Jining, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sheng-bin Shi
            affiliation:
                  name:Shan Dong Tumor Hospital
                  address:
                     name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jie-lin Qi
            affiliation:
                  name:Shan Dong Tumor Hospital
                  address:
                     name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Xiao-yong Tang
            affiliation:
                  name:Shan Dong Tumor Hospital
                  address:
                     name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jing Tian
            affiliation:
                  name:Shan Dong Tumor Hospital
                  address:
                     name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
         1357-0560
      volumeNumber:30
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Shan Dong Ji Ning First People’s Hospital
      address:
         name:Department of Internal Medicine, Shan Dong Ji Ning First People’s Hospital, Jining, People’s Republic of China
         type:PostalAddress
      name:Shan Dong Tumor Hospital
      address:
         name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
         type:PostalAddress
      name:Shan Dong Tumor Hospital
      address:
         name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
         type:PostalAddress
      name:Shan Dong Tumor Hospital
      address:
         name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
         type:PostalAddress
      name:Shan Dong Tumor Hospital
      address:
         name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Meng Wang
      affiliation:
            name:Shan Dong Ji Ning First People’s Hospital
            address:
               name:Department of Internal Medicine, Shan Dong Ji Ning First People’s Hospital, Jining, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Sheng-bin Shi
      affiliation:
            name:Shan Dong Tumor Hospital
            address:
               name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Jie-lin Qi
      affiliation:
            name:Shan Dong Tumor Hospital
            address:
               name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Xiao-yong Tang
      affiliation:
            name:Shan Dong Tumor Hospital
            address:
               name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Jing Tian
      affiliation:
            name:Shan Dong Tumor Hospital
            address:
               name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Internal Medicine, Shan Dong Ji Ning First People’s Hospital, Jining, People’s Republic of China
      name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
      name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
      name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
      name:Department of Internal Medicine, Shan Dong Tumor Hospital, Jinan, People’s Republic of China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(98)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.55s.

LINK . SPRINGER . COM {}